Investors
Clinical Force has a broad range of investors led by 3 leading Life Science entrepreneurs. Prior to the 2006 investment Clinical Force was self funding.
In addition to the Life science entrepreneurs, the investment round included US and European entrepreneurs with experience in mergers and acquisitions, product based businesses and strong FTSE 100 management experience.
The Clinical Force team is delighted to be working with a broad group of investors each bringing their own experiences and skills positively to the business. Most of the investors are led by individuals that have held executive management positions. Most of the investors have significant experience with start-ups, corporate governance, mergers and acquisitions and public offerings in Europe and the USA.
Background on Life Science Investors
Andy Richards
Dr Richards is a well known Biotechnology Entrepreneur and Business Angel having been a founder of several successful Cambridge biotechnology companies including Arakis, Cambridge Biotechnology and Daniolabs; Andy was a founder and an executive director of Chiroscience, one of Europe’s most successful biotech companies, taking the company through to the merger with Celltech in August 1999. He holds a number of non-executive director positions including Biowisdom, Babraham Bioscience Technology, Daniolabs, Vectura group plc, and Cancer Research Technology (the commercial arm of CR-UK) and is Chairman of Pharmakodex and Geneservice Ltd.
Peter Keen
Peter is a chartered accountant with over 21 years experience in the management and financing of biotechnology companies. He is Chief Financial Officer of BioProgress plc, the NASDAQ and AIM listed specialty pharmaceutical company having joined from Arakis Ltd where he was CFO until its acquisition by the Japanese biotech company Sosei, his expertise helps him transform businesses ready for a trade sale or public offering. Peter’s experience is broader than the pure operational side, having spent 7 years with the European life science venture capital firm Merlin Biosciences where he was a co-founder and UK Managing Director. During this time he supported and served on the board as a non executive director of a number of portfolio companies including Arakis, Ark Therapeutics, Biovex, Cyclacel, LiDCO, Microscience, Intercytex, ReNeuron and Vectura. Prior to this he was a co-founder and Finance Director of Chiroscience plc which listed on the LSE in 1994.
Peter is currently a non-executive director of 3 publicly quoted companies, Ark Therapeutics Group plc, the Finsbury Emerging Biotechnology Trust plc and Abcam plc.
Peter studied economics at the University of Hull before qualifying as a Chartered Accountant with Arthur Young, now part of Ernst & Young.
Tim Sharpington
Tim has broad experience of Pharmaceutical/Biotechnology and Clinical Research Organizations. Tim is Founder CEO of Serentis Pharma and before that he was Director of Clinical Operations of Arakis. Tim previously served as VP European Operations for ICON, a global clinical research organisation. Before ICON he was Director of Clinical Operations at Sequus, where he developed Doxil® through NDA to launch in the US market. He previously managed drug development programs at Pfizer including the late stage development of Zithromax®, Trovan® and Diflucan®. Tim obtained a BSc (Hons) in biochemistry at the University of Wolverhampton, followed by three years post-graduate work at the London School of Hygiene and Tropical Medicine.
Read further about the solution, sign up for a webinar to learn more or contact us for a free demo.